EyeGate Pharmaceuticals announced the top-line results for a phase 3 trial of EGP-437 for the treatment of noninfectious anterior segment uveitis, which did not demonstrate non-inferiority to a control group.
The treatment, delivered through the EyeGate II Drug Delivery System, showed clinical efficacy in reducing anterior chamber cell score but did not demonstrate non-inferiority to a prednisolone acetate ophthalmic solution control group. Non-inferiority was measured by the proportion of patients with an anterior cell count of zero at day 14, according to a press release from EyeGate.
“Although
Uncategorized